TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell...

Area of Science:

• Genetics
• Immunology
• Oncology

Background:

• Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• The noncanonical NF-κB pathway plays a role in B cell survival and lymphomagenesis.
• TRAF3 acts as a negative regulator of NF-κB signaling.

Purpose of the Study:

• To investigate the role of TRAF3 in de novo DLBCL.
• To explore the association between TRAF3 alterations and NF-κB pathway activation.
• To identify potential therapeutic targets in TRAF3-deficient DLBCL.

Main Methods:

• Analysis of chr14q32.31-32 locus deletions in DLBCL patient samples.
• Integrative analysis of gene copy number and pathway activity.
• Experimental models of DLBCL with TRAF3 genetic ablation.
• NIK inhibition studies and cytokine secretion analysis.
• Coculture experiments with T cells to assess immune microenvironment impact.

Main Results:

• Recurrent focal deletions of the chr14q32.31-32 locus, including TRAF3, were identified in 24/324 DLBCL cases.
• TRAF3 copy number loss correlated with NIK accumulation and increased noncanonical NF-κB activity.
• TRAF3 ablation in DLBCL models upregulated NIK and enhanced downstream signaling, leading to proliferation and survival.
• NIK inhibition differentially affected TRAF3-deficient DLBCL cells, suggesting onco-addiction.
• TRAF3 loss exacerbated IL-10 secretion, impairing CD8+ T cell function, which was restored by IL-10 neutralization.

Conclusions:

• Genetic alterations in TRAF3 are directly linked to noncanonical NF-κB pathway activation in DLBCL.
• NIK is a potential therapeutic target in a subset of DLBCL characterized by TRAF3 loss.
• TRAF3 deficiency contributes to an immunosuppressive tumor microenvironment via IL-10, impacting anti-tumor immunity.